170 related articles for article (PubMed ID: 8860970)
1. Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects.
Yagi N; Kiuchi T; Satoh H; Terashima Y; Kenmotsu H; Sekikawa H; Takada M
Biol Pharm Bull; 1996 Apr; 19(4):616-22. PubMed ID: 8860970
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability and diuretic effect after administration of retarded capsules of bumetanide in human subjects.
Yagi N; Kiuchi T; Satoh H; Ishikawa Y; Takada M; Sekikawa H
Biol Pharm Bull; 1999 Mar; 22(3):275-80. PubMed ID: 10220284
[TBL] [Abstract][Full Text] [Related]
3. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations.
Ozdemir N; Ordu S; Ozkan Y
Drug Dev Ind Pharm; 2000 Aug; 26(8):857-66. PubMed ID: 10900542
[TBL] [Abstract][Full Text] [Related]
4. Prolonged-release hydroxypropyl methylcellulose matrix tablets of furosemide for administration to dogs.
Smal J; Marvola M; Liljequist C; Happonen I
J Vet Pharmacol Ther; 1996 Dec; 19(6):482-7. PubMed ID: 8971678
[TBL] [Abstract][Full Text] [Related]
5. Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men.
Waller ES; Crismon ML; Smith RV; Bauza MT; Doluisio JT
Biopharm Drug Dispos; 1988; 9(2):211-8. PubMed ID: 3370308
[TBL] [Abstract][Full Text] [Related]
6. Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.
Alván G; Paintaud G; Eckernäs SA; Grahnén A
Br J Clin Pharmacol; 1992 Jul; 34(1):47-52. PubMed ID: 1633067
[TBL] [Abstract][Full Text] [Related]
7. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
Otsuka K; Wagner C; Selen A; Dressman J
J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
[TBL] [Abstract][Full Text] [Related]
8. Variable furosemide absorption and poor predictability of response in elderly patients.
Murray MD; Haag KM; Black PK; Hall SD; Brater DC
Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
[TBL] [Abstract][Full Text] [Related]
10. A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section.
Gonçalves PVB; Moreira FL; Benzi JRL; Duarte G; Lanchote VL
J Clin Pharmacol; 2020 Dec; 60(12):1655-1661. PubMed ID: 32562572
[TBL] [Abstract][Full Text] [Related]
11. Population-based meta-analysis of furosemide pharmacokinetics.
Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
Biopharm Drug Dispos; 2014 Mar; 35(2):119-33. PubMed ID: 24151207
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum.
Lee WI; Yoon WH; Shin WG; Song IS; Lee MG
Biopharm Drug Dispos; 1997 Dec; 18(9):753-67. PubMed ID: 9429740
[TBL] [Abstract][Full Text] [Related]
13. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
Rasool BK; Fahmy SA; Galeel OW
Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
[TBL] [Abstract][Full Text] [Related]
14. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
[TBL] [Abstract][Full Text] [Related]
15. Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans.
Vree TB; van der Ven AJ
J Pharm Pharmacol; 1999 Mar; 51(3):239-48. PubMed ID: 10344623
[TBL] [Abstract][Full Text] [Related]
16. Intermittent bolus injection versus continuous infusion of furosemide in normal adult greyhound dogs.
Adin DB; Taylor AW; Hill RC; Scott KC; Martin FG
J Vet Intern Med; 2003; 17(5):632-6. PubMed ID: 14529128
[TBL] [Abstract][Full Text] [Related]
17. In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations.
Cuadrado A; Rodríguez Gascón A; Hernández RM; Castilla AM; de la Maza A; Yánez C; López de Ocáriz A; Solinís MA; Pedraz JL
Arzneimittelforschung; 2003; 53(5):321-9. PubMed ID: 12854359
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of two preparations of furosemide and their pharmacological activity in normal volunteers.
Ogata H; Zugarni S; Ejima A; Kawatsu Y
Eur J Clin Pharmacol; 1983; 24(6):791-6. PubMed ID: 6688397
[TBL] [Abstract][Full Text] [Related]
19. Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects.
Johansson AM; Gardner SY; Levine JF; Papich MG; LaFevers DH; Fuquay LR; Reagan VH; Atkins CE
J Vet Intern Med; 2003; 17(6):887-95. PubMed ID: 14658727
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects.
Abou-Auda HS
Int J Clin Pharmacol Ther; 1998 May; 36(5):275-81. PubMed ID: 9629992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
